Short- (30-90 days) and mid-term (1-3 years) outcomes and prognostic factors of patients with esophageal cancer undergoing surgical treatments

Table 1 Baseline characteristics of the patients (n = 307)

Characteristics	Median (range) / n (%)
Age (yr)	64 (44, 79)
Body mass index (kg/m2)	22.2 (14.9, 31.6)
Disease course (months)	2 (0.1, 36)
Sex (male)	195 (63.5%)
Smoking	95 (30.9%)
Drinking	20 (6.5%)
Family history of esophagus cancer	22 (7.2%)
Hypertension	112 (36.5%)
Diabetes	21 (6.8%)
Coronary heart disease	16 (5.2%)
ASA stage
II	233 (75.9%)
III	73 (23.8%)
IV	1 (0.3%)
Hemoglobin (g/L)	141 (80, 180.4)
MCV (fl)	93.6 (71.1, 134.1)
Platelets (× 109/L)	213 (60.3, 445.9)
Lymphocytes (× 109/L)	1.56 (0.07, 7.42)
Monocytes (× 109/L)	0.36 (0.05, 1.01)
Neutrophils (× 109/L)	3.63 (1.15, 12.94)
PT (s)	13.8 (11.4, 31.9)
APTT (s)	31.4 (10.6, 51.7)
Fibrinogen (g/L)	3.79 (1.95, 6.3)
D-dimer (ng/mL)	130 (14, 3354)
Total protein (g/L)	71 (3.32, 88.1)
Albumin (g/L)	42.1 (26.1, 63.5)
Creatinine (µmol/L)	63 (36, 187)
Hematocrit (%)	46.6 (28.2, 64.5)

ASA: American Society of Anesthesiologists; MCV: Mean corpuscular volume; PT: Prothrombin time; APTT; Activated partial thromboplastin time.